# US 2022/0033778 A1 · Methods for ex vivo expansion of natural killer cells and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033778 A1
- Document ID: US20220033778A1
- Status: Published application
- Kind: A1
- Application number: 17/309,426
- Filed: 2019-11-21
- Published: 2022-02-03
- Earliest claimed: 2018-11-29
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Elizabeth Shpall; Katy Rezvani
- Web page: https://patentgrep.com/patent/US20220033778A1

## CPC

- C07K 14/5418: {IL-7}
- C07K 16/2803: {against the immunoglobulin superfamily}
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/15: Natural-killer [NK] cells; Natural-killer T [NKT] cells
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 14/54: Interleukins [IL]
- C07K 14/5421: {IL-8}
- C07K 14/5443: {IL-15}
- C07K 14/55: IL-2
- C07K 14/70503: {Immunoglobulin superfamily}
- C12N 5/0087: {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- C12N 5/0646: {Natural killers cells [NK], NKT cells}
- A61K 2039/804: {Blood cells [leukemia, lymphoma]}
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C12N 2501/2302: Interleukin-2 (IL-2)
- C12N 2501/2315: Interleukin-15 (IL-15)
- C12N 2501/2321: Interleukin-21 (IL-21)
- C12N 2501/53: CD2
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2502/11: blood or immune system cells
- C12N 2502/99: genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are ex vivo methods for the expansion of cord blood-derived natural killer cells and methods of their use. Examples of embodiments include stimulating mononuclear cells from cord blood in the presence of antigen presenting cells (APCs) and IL-2 and re-stimulating the cells with APCs to produce expanded NK cells. In specific embodiments, the method does not utilize human leukocyte antigen (HLA) matching.

## Claims

### Claim 1

An ex vivo method for the expansion of natural killer (NK) cells comprising:
(a) obtaining a starting population of mononuclear cells (MNCs) from cord blood;
(b) stimulating the MNCs in the presence of antigen presenting cells (APCs) and IL-2; and
(c) re-stimulating the cells with APCs to produce expanded NK cells, wherein the method is performed in a bioreactor and is good manufacturing practice (GMP) compliant.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises depleting cells positive for CD3.

### Claim 3 (depends on 2)

The method of claim 2, wherein the depleting is performed between steps (b) and (c).

### Claim 4 (depends on 3)

The method of claim 3, wherein the cells are removed from the bioreactor.

### Claim 5 (depends on 1)

The method of claim 1, wherein obtain the starting population of MNCs from cord blood comprises thawing cord blood in the presence of dextran, human serum albumin (HSA), DNAse, and/or magnesium chloride.

### Claim 6 (depends on 1)

The method of claim 1, wherein obtain the starting population of MNCs from cord blood comprises thawing cord blood in the presence of dextran and DNase.

### Claim 7 (depends on 5)

The method of claim 5, wherein the cord blood is washed in the presence of 10% dextran.

### Claim 8 (depends on 5, 7)

The method of claim 5 or 7, wherein the cord blood is suspended in the presence of magnesium chloride.

### Claim 9 (depends on 8)

The method of claim 8, wherein the magnesium chloride is at a concentration of 200 mM.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any of claims 1-9, wherein obtaining comprises performing ficoll density gradient centrifugation to obtain mononuclear cells (MNCs).

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any of claims 1-10, wherein the method does not comprise removal or addition of any media components during step (b).

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The method of any of claims 1-11, wherein the bioreactor is a gas permeable bioreactor.

### Claim 13 (depends on 12)

The method of claim 12, wherein the gas permeable bioreactor is G-Rex100M.

### Claim 14 (depends on 13)

The method of claim 13, wherein the stimulating of step (b) is performed in 3-5 L of media.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any of claims 1-13, wherein the APCs are gamma-irradiated.

### Claim 16 (depends on 15)

The method of claim 15, wherein the APCs are engineered to express membrane-bound IL-21 (mbIL-21).

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 1-16, wherein the APCs are engineered to express IL-21, IL-15, IL-7, IL-18, and/or IL-2.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any of claims 1-16, wherein the MNCs and APCs are cultured at a ratio of 1:2.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any of claims 1-18, wherein the IL-2 is at a concentration of 50-200 IU/mL.

### Claim 20 (depends on 19)

The method of claim 19, wherein the IL-2 is at a concentration of 100 IU/mL.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 1-20, wherein the IL-2 is replenished every 2-3 days.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any of claims 1-20, wherein step (b) is performed for 6-8 days.

### Claim 23 (depends on 22)

The method of claim 22, wherein step (b) is performed for 7 days.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein step (b) does not comprise splitting of the cells.

### Claim 25 (depends on 24)

The method of claim 24, wherein the cells are fed twice with IL-2.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The method of any of claims 1-25, wherein the method comprises the use of 3, 4, 5, or 6 bioreactors.

### Claim 27 (depends on 26)

The method of claim 26, wherein the method comprises the use of less than 10 bioreactors.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any of claims 1-27, wherein the NK cells are expanded at least 500-fold, 800-fold, 1000-fold, 3000-fold, or 5000-fold.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any of claims 1-28, wherein culturing the NK cells in the bioreactor produces more than 1000-fold NK cells as compared to static liquid culture.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any of claims 1-29, wherein the method does not comprise human leukocyte antigen (HLA) matching.

### Claim 31 (depends on 30)

The method of claim 30, wherein the starting population of NK cells are not obtained from a haploidentical donor.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any of claims 1-31, wherein the method is performed in less than 15 days.

### Claim 33 (depends on 32)

The method of claim 32, wherein the method is performed in 14 days.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The method of any of claims 1-33 wherein the expanded NK cells have enhanced anti-tumor activity as comprises to NK cells expanded from peripheral blood.

### Claim 35 (depends on 34)

The method of claim 34, wherein the expanded NK cells have higher expression of cell cycle, cell division, and/or DNA replication genes as compared to NK cells expanded from peripheral blood.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The method of any of claims 1-34, wherein the expanded NK cells have higher proliferative capacity as compared to NK cells expanded from peripheral blood.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

The method of any of claim 1-36, wherein the expanded NK cells do not exhibit exhaustion.

### Claim 38 (depends on 37)

The method of claim 37, wherein exhaustion is detected by measuring expression of perforin, granzyme, CD57, KLRG1, and PD1.

### Claim 39 (depends on 38)

The method of claim 38, wherein the expanded NK cells have high expression of perforin and granzyme.

### Claim 40 (depends on 38)

The method of claim 38, wherein the expanded NK cells have low or no expression of CD57, KLRG1, and PD1.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The method of any of claims 1-40, wherein the expanded NK cells comprise a clinically relevant dose.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)

The method of any of claims 1-41, wherein the cord blood is frozen cord blood.

### Claim 43 (depends on 42)

The method of claim 42, wherein the frozen cord blood has been tested for infectious disease.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any of claims 1-43, wherein the cord blood is pooled cord blood.

### Claim 45 (depends on 44)

The method of claim 44, wherein the cord blood is pooled from 3, 4, 5, 6, 7, or 8 individual cord blood units.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The method of any of claims 1-45, wherein the NK cells are not autologous.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any of claims 1-46, wherein the NK cells are not allogeneic.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any of claims 1-47, wherein the APCs are universal antigen presenting cells (uAPCs).

### Claim 49 (depends on 48)

The method of claim 48, wherein the uAPCs are engineered to express (1) CD48 and/or CS1 (CD319), (2) membrane-bound interleukin-21 (mbIL-21), and (3) 41BB ligand (41BBL).

### Claim 50 (depends on 48)

The method of claim 48, wherein the uAPCs express CD48.

### Claim 51 (depends on 48)

The method of claim 48, wherein the uAPCs express CS1.

### Claim 52 (depends on 48)

The method of claim 48, wherein the uAPCs express CD48 and CS1.

### Claim 53 (depends on 48)

The method of claim 48, wherein the uAPCs have essentially no expression of endogenous HLA class I, II, or CD1d molecules.

### Claim 54 (depends on 48)

The method of claim 48, wherein the uAPCs express ICAM-1 (CD54) and LFA-3 (CD58).

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any of claims 1-54, wherein the uAPCs are further defined as leukemia cell-derived aAPCs.

### Claim 56 (depends on 55)

The method of claim 55, wherein the leukemia-cell derived aAPCs are further defined as K562 cells.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any of claims 1-56, further comprising cryopreserving the expanded NK cells.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A pharmaceutical composition comprising a population of NK cells produced by any one of claims 1-57 and a pharmaceutically acceptable carrier.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A composition comprising an effective amount of NK cells produced by any one of claims 1-57 for use in the treatment of a disease or disorder in a subject.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The use of a composition comprising an effective amount of NK cells produced by any one of claims 1-57 for the treatment of an immune-related disorder in a subject.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

A method for treating a disease or disorder comprising administering an effective amount of expanded NK cells according to any of claims 1-57 to the subject.

### Claim 62 (depends on 61)

The method of claim 61, further comprising administering chemotherapy.

### Claim 63 (depends on 62)

The method of claim 62, wherein the chemotherapy is administered prior to the expanded NK cells.

### Claim 64 (depends on 62, 63)

The method of claim 62 or 63, wherein the chemotherapy is myeloablative.

### Claim 65 (depends on 62, 63)

The method of claim 62 or 63, wherein the chemotherapy is non-myeloablative.

### Claim 66 (depends on 62, 63)

The method of claim 62 or 63, wherein the chemotherapy is lymphodepleting chemotherapy.

### Claim 67 (depends on 66)

The method of claim 66, wherein the lymphodepleting chemotherapy is fludarabine-based lymphodepleting chemotherapy.

### Claim 68 (depends on 62, 63, 64, 65, 66, 67)

The method of any of claims 62-67, wherein the chemotherapy is lenalidomide.

### Claim 69 (depends on 62, 63, 64, 65, 66, 67, 68)

The method of any of claims 62-68, wherein the method does not comprise performing HLA matching.

### Claim 70 (depends on 62, 63, 64, 65, 66, 67, 68, 69)

The method of any of claims 62-69, wherein the disease or disorder is an immune-related disorder.

### Claim 71 (depends on 70)

The method of claim 70, wherein the immune-related disorder is an autoimmune disorder, graft versus host disease, allograft rejection, or inflammatory condition.

### Claim 72 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any of claims 61-69, wherein the disease or disorder is cancer.

### Claim 73 (depends on 72)

The method of claim 72, wherein the cancer is multiple myeloma.

### Claim 74 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any of claims 61-73, wherein the subject does not develop graft versus host disease or other toxicity.

### Claim 75 (depends on 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any of claims 61-74, further comprising administering an effective amount of at least a second therapeutic agent.

### Claim 75 (depends on 75)

The method of claim 75, wherein the at least a second therapeutic agent comprises chemotherapy, immunotherapy, surgery, radiotherapy, or biotherapy.

### Claim 77 (depends on 75)

The method of claim 75, wherein the NK cells and/or the at least a second therapeutic agent are administered intravenously, intraperitoneally, intratracheally, intratumorally, intramuscularly, endoscopically, intralesionally, percutaneously, subcutaneously, regionally, or by direct injection or perfusion.

### Claim 78 (depends on 75, 76, 77)

The method of any one of claims 75-77, wherein the second therapeutic agent comprises elotuzamab.
